Compile Data Set for Download or QSAR
Report error Found 240 Enz. Inhib. hit(s) with Target = 'Tyrosine-protein kinase JAK3 [512-1124]'
TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493096BDBM493096(US10981911, Example 36 | N-((1H-imidazol-2-yl)meth...)
Affinity DataIC50: 12nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 387815BDBM387815(US10294226, Compound A | US10487083, Example A | U...)
Affinity DataIC50: 12.4nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/20/2020
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 505104BDBM505104(US11066406, A)
Affinity DataIC50: 12.4nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493067BDBM493067(US10981911, Example 8 | 2-(1-((1r,4r)-4-(Cyanometh...)
Affinity DataIC50: 12.9nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493258BDBM493258(US10981911, Example 188 | 2-(8-chloro-1-((1r,4r)-4...)
Affinity DataIC50: 13.1nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493066BDBM493066(US10981911, Example 7 | 2-(1-((1r,4r)-4-(Cyanometh...)
Affinity DataIC50: 13.3nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 420028BDBM420028(US10487083, Example B)
Affinity DataIC50: 13.4nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
9/20/2020
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 505105BDBM505105(US11066406, B)
Affinity DataIC50: 13.4nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493279BDBM493279(US10981911, Example 200 | 2-(1-((1r,4r)-4-(Cyanome...)
Affinity DataIC50: 13.7nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493259BDBM493259(US10981911, Example 189 | 2-(8-bromo-1-((1r,4r)-4-...)
Affinity DataIC50: 16.6nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493156BDBM493156(US10981911, Example 95 | (EZ)—N-((1-((1r,4r)-...)
Affinity DataIC50: 18.7nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493126BDBM493126(US10981911, Example 66 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 18.9nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493101BDBM493101(US10981911, Example 41 | 2-((1r,4r)-4-(2-(Thiazol-...)
Affinity DataIC50: 19.9nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493080BDBM493080(US10981911, Example 20 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 20.5nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 387822BDBM387822(US10294226, Compound Ex. 5 | 2-(1-((1r,4r)-4-(Cyan...)
Affinity DataIC50: 23.1nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 505111BDBM505111(US11066406, Ex. 5)
Affinity DataIC50: 23.1nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 387822BDBM387822(US10294226, Compound Ex. 5 | 2-(1-((1r,4r)-4-(Cyan...)
Affinity DataIC50: 23.1nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/20/2020
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493269BDBM493269(US10981911, Example 198 | 2-(1-((1r,4r)-4-(Cyanome...)
Affinity DataIC50: 24.4nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 387823BDBM387823(US10294226, Compound Ex. 6 | 2-(1-((1r,4r)-4-(Cyan...)
Affinity DataIC50: 28.2nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/20/2020
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 505112BDBM505112(US11066406, Ex. 6)
Affinity DataIC50: 28.2nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 387823BDBM387823(US10294226, Compound Ex. 6 | 2-(1-((1r,4r)-4-(Cyan...)
Affinity DataIC50: 28.2nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493143BDBM493143(US10981911, Example 83 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 30nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 387828BDBM387828(US10294226, Compound Ex. 11 | 2-(1-((1r,4r)-4-(Cya...)
Affinity DataIC50: 30.3nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/20/2020
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 387828BDBM387828(US10294226, Compound Ex. 11 | 2-(1-((1r,4r)-4-(Cya...)
Affinity DataIC50: 30.3nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 505117BDBM505117(US11066406, Ex. 11)
Affinity DataIC50: 30.3nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 50527404BDBM50527404(CHEMBL4514898 | US10981911, Example 62)
Affinity DataIC50: 30.6nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 50527409BDBM50527409(CHEMBL4447497 | US10981911, Example 58)
Affinity DataIC50: 31.4nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493079BDBM493079(US10981911, Example 19 | N-((1r,4r)-4-(Cyanomethyl...)
Affinity DataIC50: 31.8nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493088BDBM493088(US10981911, Example 28 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 32.7nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493116BDBM493116(US10981911, Example 56 | 2-((1r,4r)-4-(2-(1H-Imida...)
Affinity DataIC50: 32.9nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493169BDBM493169(US10981911, Example 108 | Diethyl 4-(2-(1-((1r,4r)...)
Affinity DataIC50: 32.9nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493070BDBM493070(US10981911, Example 11 | 2-((1r,4r)-4-(2-(Oxazol-4...)
Affinity DataIC50: 33.5nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 387819BDBM387819(US10294226, Compound Ex. 2 | 2-((1r,4r)-4-(2-(1H-I...)
Affinity DataIC50: 33.9nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/20/2020
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 505108BDBM505108(US11066406, Ex. 2)
Affinity DataIC50: 33.9nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 387819BDBM387819(US10294226, Compound Ex. 2 | 2-((1r,4r)-4-(2-(1H-I...)
Affinity DataIC50: 33.9nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493087BDBM493087(US10981911, Example 27 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 36.9nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493075BDBM493075(US10981911, Example 16 | 2-((1r,4r)-4-(2-(2H-1,2,3...)
Affinity DataIC50: 37.7nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 50527407BDBM50527407(CHEMBL4582390 | US10981911, Example 33)
Affinity DataIC50: 38nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493083BDBM493083(US10981911, Example 23 | N-(4-Cyanobicyclo[2.2.1]h...)
Affinity DataIC50: 38.1nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493097BDBM493097(US10981911, Example 37 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 38.8nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493107BDBM493107(US10981911, Example 47 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 38.9nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493114BDBM493114(US10981911, Example 54 | 4-(2-(1-((1r,4r)-4-(Cyano...)
Affinity DataIC50: 42nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 387825BDBM387825(US10294226, Compound Ex. 8 | 2-(1-((1r,4r)-4-(Cyan...)
Affinity DataIC50: 42.5nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493073BDBM493073(US10981911, Example 14 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 43.7nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493100BDBM493100(US10981911, Example 40 | 1-((1-((1r,4r)-4-(Cyanome...)
Affinity DataIC50: 47nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493281BDBM493281(US10981911, Example 201 | 2-(1-((1r,4r)-4-(Cyanome...)
Affinity DataIC50: 47.5nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493068BDBM493068(US10981911, Example 9 | 2-((1r,4r)-4-(2-(1H-1,2,4-...)
Affinity DataIC50: 48.9nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 493065BDBM493065(US10981911, Example 6 | 2-((1r,4r)-4-(2-(2-Oxo-2-(...)
Affinity DataIC50: 49.4nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 50434787BDBM50434787(CHEMBL2386635 | US10703751, Example 644 of WO20110...)
Affinity DataIC50: 49.7nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/20/2020
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 505106BDBM505106(US11066406, C)
Affinity DataIC50: 49.7nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2021
Entry Details
US Patent

Displayed 1 to 50 (of 240 total ) | Next | Last >>
Jump to: